7-(6-fluoropyridin-3-yl)-5-methyl-5H-pyrido[4,3-b]indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-(6-fluoropyridin-3-yl)-5-methyl-5H-pyrido[4,3-b]indole
• 英文别名: 7-(6-Fluoropyridin-3-yl)-5-methylpyrido[4,3-b]indole；7-(6-fluoropyridin-3-yl)-5-methylpyrido[4,3-b]indole
• 化学式: C₁₇H₁₂FN₃
• 分子量: 277.301
• InChiKey: QVXVWQKQQUVYOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-(6-fluoropyridin-3-yl)-5-methyl-5H-pyrido[4,3-b]indole 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 sodium hydride 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-(2,6-dioxopiperidin-3-yl)-5-((6-(6-(3-((5-(5-methyl-5H-pyrido[4,3-b]indol-7-yl)pyridin-2-yl)oxy)propoxy)pyridin-3-yl)hex-5-yn-1-yl)oxy)isoindolin-1,3-dione
  参考文献：
  名称：

  TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

  摘要：

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。

  公开号：

  US20180125821A1

文献信息

• CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME
  申请人：Arvinas, Inc.

  公开号：US20180215731A1

  公开（公告）日：2018-08-02

  The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

  该描述涉及cereblon E3连接酶结合化合物，包括包含相同成分的双功能化合物，这些化合物作为靶向泛素化的调节剂具有实用价值，尤其是抑制剂，可降解和/或以其他方式抑制根据本公开的双功能化合物。特别是，该描述提供了化合物，其一端含有与cereblon E3泛素连接酶结合的配体，另一端含有与目标蛋白结合的部分，使目标蛋白位于泛素连接酶附近以降解（和抑制）该蛋白。可以合成表现出广泛药理活性的化合物，与几乎所有类型的靶向多肽的降解/抑制一致。
• Imaging Agents for Detecting Neurological Dysfunction
  申请人：Szardenings Anna Katrin

  公开号：US20120302755A1

  公开（公告）日：2012-11-29

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

  本文公开了一种诊断哺乳动物阿尔茨海默病或其易感性的化合物和方法，其中该方法包括向哺乳动物施加诊断有效量的放射性标记化合物，所述化合物选自放射性标记的咔唑衍生物和其衍生物以及三唑衍生物组成的群体，允许该化合物分布到脑组织中，并成像脑组织，其中与正常控制结合水平相比，化合物对脑组织的结合增加表明哺乳动物正在患有或有发展阿尔茨海默病的风险。
• Imaging agents for detecting neurological dysfunction
  申请人：Eli Lilly and Company

  公开号：US20150030540A1

  公开（公告）日：2015-01-29

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

  本文中披露了在哺乳动物中诊断阿尔茨海默病或其易感性的化合物和方法，该方法包括向哺乳动物施用诊断有效量的放射性标记化合物，所述化合物选自放射性标记的咔唑衍生物和其衍生物以及三唑衍生物的群组，使化合物分布到脑组织中，并成像脑组织，其中化合物与脑组织的结合增加，与正常对照水平的结合相比，表明哺乳动物正在患有或有发展阿尔茨海默病的风险。
• WO2021011913A5
  申请人：——

  公开号：WO2021011913A5

  公开（公告）日：2023-07-25
• TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：EP3999182A1

  公开（公告）日：2022-05-25